Skip to content

Rotterdam Aphasia Therapy Study - 2.

The efficacy of cognitive linguistic therapy in the acute stage of aphasia: a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25719
Enrollment
160
Registered
2005-07-21
Start date
2006-09-04
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Experimental condition: CLT 0-6 m.p.o Control condition: no-CLT 0-6 m.p.o 2. Experimental condition: CLT 0-3 m.p.o. followed by no-CLT 3-6 m.p.o. Control condition: no-CLT 0-3 m.p.o. followed by CLT 3-6 m.p.o.

Interventions

Assessment: - Amsterdam-Nijmegen Everyday Language Test (ANELT), scale A - ScreeLing - Semantic Association Test (SAT), verbal version - Semantic Association words with low imageability (PALPA) - sema

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aphasia due to stroke; 2. Within 3 weeks post onset; 3. Age 18-85 years; 4. Language near native Dutch; 5. Life expectancy > 6 months.

Exclusion criteria

Exclusion criteria: 1. Severe dysarthria; 2. Premorbid dementia; 3. Illiteracy; 4. Severe developmental dyslexia; 5. Severe visual perceptual disorders; 6.Existing aphasia; 7. Subarachnoidal haemorrhage; 8. Recent psychiatric disorder.

Design outcomes

Primary

MeasureTime frame
The score at 6 months post onset on the Amsterdam Nijmegen Everyday Language Test (ANELT), scale A (Understandability).

Secondary

MeasureTime frame
- Proportion of patients in each treatment group who improve at least 7 points on the ANELT - A categorization of the ANELT into severe (score, 10-29) and moderate to mild (score, 30-48) communication deficits - ScreeLing; Semantic Association Test (SAT), verbal version; Semantic Association words with low imageability, Nonwords Repetition and Auditory Lexical Decision (PALPA); semantic word fluency; letter fluency.

Contacts

Public ContactM. Hagelstein

Erasmus Medical Center, Molewaterplein 40, P.O. Box 2060

m.hagelstein@erasmusmc.nl+31 (0)10 4087414

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)